Positive conversion of PD-L1 expression after treatments with chemotherapy and nivolumab

Naoki Haratake, Gouji Toyokawa, Tetsuzo Tagawa, Yuka Kozuma, Taichi Matsubara, Shinkichi Takamori, Takaki Akamine, Yuichi Yamada, Yoshinao Oda, Yoshihiko Maehara

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)


Background/Aim: Few studies have so far described the conversion of programmed death-ligand 1 (PD-L1) after treatment. In particular, the effect of nivolumab on the PD-L1 expression has never been reported. We investigated the changes in PD-L1 expression after chemotherapy and nivolumab treatment and herein describe the detailed clinical course. Patients and Methods: We retrospectively examined the PD-L1 expression in resected specimens and in the re-biopsy specimens of patients with non-small cell lung cancer by immunohistochemical analysis. Results: Four patients underwent a re-biopsy after treatment. Of those, three showed positive conversion of the PD-L1 expression. One patient underwent a re-biopsy after chemotherapy and nivolumab treatment, and the other two cases underwent a re-biopsy after chemotherapy, radiotherapy and nivolumab treatment. Conclusion: These cases suggest the positive conversion of PD-L1 expression after treatments including nivolumab, suggesting that PD-L1 expression must be assessed in not only the resected specimens, but also in the re-biopsied ones.

Original languageEnglish
Pages (from-to)5713-5717
Number of pages5
JournalAnticancer research
Issue number10
Publication statusPublished - Oct 2017

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Positive conversion of PD-L1 expression after treatments with chemotherapy and nivolumab'. Together they form a unique fingerprint.

Cite this